United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total value of $3,724,950.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $32,282.90. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
United Therapeutics Stock Performance
Shares of NASDAQ UTHR opened at $243.27 on Thursday. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The stock has a 50 day moving average of $225.55 and a 200-day moving average of $227.39. The company has a market capitalization of $11.45 billion, a P/E ratio of 12.26 and a beta of 0.52.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating analysts' consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company's revenue for the quarter was up 25.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.67 EPS. As a group, equities research analysts predict that United Therapeutics Co. will post 23.32 EPS for the current year.
Analyst Ratings Changes
Protect Your Bank Account Before It’s Too Late
From Weiss Ratings | Ad
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account.
It gives them the power to monitor every single transaction …
Stop right now and do these 3 things to protect yourself
A number of research analysts recently commented on the company. HC Wainwright restated a "buy" rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. The Goldman Sachs Group upgraded United Therapeutics from a "sell" rating to a "neutral" rating and upped their price target for the company from $213.00 to $215.00 in a research report on Monday, February 12th. Wells Fargo & Company increased their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an "overweight" rating in a report on Thursday, March 7th. Wedbush restated an "outperform" rating and set a $308.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, SVB Leerink began coverage on United Therapeutics in a report on Monday, February 5th. They set an "outperform" rating and a $330.00 target price on the stock. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $294.40.
Get Our Latest Research Report on UTHR
Hedge Funds Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of UTHR. Great West Life Assurance Co. Can increased its holdings in United Therapeutics by 8.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 28,326 shares of the biotechnology company's stock worth $5,244,000 after purchasing an additional 2,320 shares in the last quarter. Canada Pension Plan Investment Board increased its stake in shares of United Therapeutics by 229.6% in the first quarter. Canada Pension Plan Investment Board now owns 2,063 shares of the biotechnology company's stock valued at $371,000 after buying an additional 1,437 shares during the period. Prudential PLC acquired a new stake in shares of United Therapeutics in the first quarter valued at about $1,160,000. Zions Bancorporation N.A. acquired a new stake in shares of United Therapeutics in the first quarter valued at about $66,000. Finally, Covestor Ltd increased its stake in shares of United Therapeutics by 187.5% in the first quarter. Covestor Ltd now owns 877 shares of the biotechnology company's stock valued at $157,000 after buying an additional 572 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
